Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Tereza Planck

Physician

Default user image.

Treatment of patients with Graves’ disease in Sweden compared to international surveys of an ‘index patient’

Author

  • Gabriel Sjölin
  • Kristina Byström
  • Mats Holmberg
  • Ove Törring
  • Selwan Khamisi
  • Jan Calissendorff
  • Mikael Lantz
  • Bengt Hallengren
  • Helena Filipsson Nyström
  • Tereza Planck
  • Göran Wallin

Summary, in English

Introduction: The treatment strategies for a 42-year-old female index patient with moderate Graves’ disease (GD) vary according to several international surveys. The important question whether surveys of treatment preferences in theoretical patient cases also match how real patients are treated has not yet been addressed. Materials and Methods: From a Swedish cohort of 1186 GD patients (TT-12 cohort), 27 women were identified using the same criteria as from the index patient surveys from the European and American Thyroid Associations. This ‘index patient cohort’ was age 40–45, otherwise healthy female, with two children and uncomplicated GD. The applied first-line treatment of the patients in the index cohort, together with its variations, was compared with the treatment preferences according to international surveys. A comparison with the TT-12 cohort was also performed. Results: In the ‘Index cohort’, 77.8% were treated with antithyroid drugs (ATD), and 22.2% were treated with radioiodine (131I). This preference for ATD is in line with most countries/regions, with the exception of USA and the Middle East/North Africa, where 131I was preferred. The distribution of treatment in the TT-12 cohort did not significantly differ from the index cohort. ATD was the preferred treatment in male and young (age 19–22) patients, as was RAI in old (age 69–73) patients. The age-related, but not the gender-related, cases differed significantly from the entire TT-12 cohort. Conclusion: The treatment choice in an index patient in Sweden seems in line with European practice, where ATD is the preferred first choice. This differs compared to US and North African survey intentions, where 131I is more often used. Age more than gender influences the treatment choice of GD patients. This is, to our best knowledge, the first time an index patient from ‘real life’ has been presented and compared to treatment preferences of international thyroid association surveys.

Department/s

  • Genomics, Diabetes and Endocrinology
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year

2021

Language

English

Publication/Series

Endocrinology, Diabetes and Metabolism

Document type

Journal article

Publisher

John Wiley and Sons

Topic

  • Endocrinology and Diabetes

Keywords

  • antithyroid drugs
  • Graves’ disease
  • hyperthyroidism
  • index patient
  • international surveys
  • long-term follow-up
  • radioactive iodine
  • thyroidectomy
  • treatment options

Status

Epub

Research group

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Other

  • ISSN: 2398-9238